Design Therapeutics, Inc.
DSGN
Price:
$5.51
Market Cap:
$311.98M
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment o...[Read more]
Industry
Biotechnology
IPO Date
2021-03-29
Stock Exchange
NASDAQ
Ticker
DSGN
The ROE as of September 2024 (TTM) for Design Therapeutics, Inc. (DSGN) is -18.48%
According to Design Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -18.48%. This represents a change of 300.98% compared to the average of -4.61% of the last 4 quarters.
Design Therapeutics, Inc. (DSGN) Historical ROE (quarterly & annually)
How has DSGN ROE performed in the past?
The mean historical ROE of Design Therapeutics, Inc. over the last ten years is 15.62%. The current -18.48% ROE has changed -218.34% with respect to the historical average. Over the past ten years (40 quarters), DSGN's ROE was at its highest in in the December 2020 quarter at 34.07%. The ROE was at its lowest in in the June 2023 quarter at -6.72%.
Average
15.62%
Median
-9.30%
Minimum
-24.08%
Maximum
73.18%
Design Therapeutics, Inc. (DSGN) ROE by Quarter and Year
Discovering the peaks and valleys of Design Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 92.59%
Maximum Annual ROE = 73.18%
Minimum Annual Increase = -112.71%
Minimum Annual ROE = -24.08%
| Year | ROE | Change |
|---|---|---|
| 2023 | -24.08% | 34.45% |
| 2022 | -17.91% | 92.59% |
| 2021 | -9.30% | -112.71% |
| 2020 | 73.18% | 30.20% |
Design Therapeutics, Inc. (DSGN) Average ROE
How has DSGN ROE performed in the past?
The current ROE of Design Therapeutics, Inc. (DSGN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-17.10%
5-year avg
15.62%
10-year avg
15.62%
Design Therapeutics, Inc. (DSGN) ROE vs. Peers
How is DSGN’s ROE compared to its peers?
Design Therapeutics, Inc.’s ROE is greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Achilles Therapeutics plc (-47.36%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Graphite Bio, Inc. (-57.96%), greater than ALX Oncology Holdings Inc. (-946.88%), greater than Aadi Bioscience, Inc. (-66.67%), less than ADC Therapeutics SA (163.46%), greater than AlloVir, Inc. (-96.48%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Erasca, Inc. (-131.94%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Immunocore Holdings plc (-17.57%), greater than C4 Therapeutics, Inc. (-44.60%),
| Company | ROE | Market cap |
|---|---|---|
| -70.40% | $346.76M | |
| -48.25% | $92.65M | |
| -42.81% | $83.00M | |
| -57.89% | $776.29M | |
| -47.36% | $28.99M | |
| -47.64% | $8.20M | |
| -61.71% | $42.44M | |
| -57.96% | $185.19M | |
| -946.88% | $114.30M | |
| -66.67% | $45.54M | |
| 163.46% | $299.61M | |
| -96.48% | $87.47M | |
| -37.20% | $989.87M | |
| -24.51% | $181.50M | |
| -131.94% | $785.36M | |
| -28.37% | $978.65M | |
| -17.57% | $1.65B | |
| -44.60% | $437.52M |
Build a custom stock screener for Design Therapeutics, Inc. (DSGN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Design Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Design Therapeutics, Inc. (DSGN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Design Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Design Therapeutics, Inc.'s ROE?
How is the ROE calculated for Design Therapeutics, Inc. (DSGN)?
What is the highest ROE for Design Therapeutics, Inc. (DSGN)?
What is the 3-year average ROE for Design Therapeutics, Inc. (DSGN)?
What is the 5-year average ROE for Design Therapeutics, Inc. (DSGN)?
How does the current ROE for Design Therapeutics, Inc. (DSGN) compare to its historical average?